Emily Lin

US Patent:

20200289845, Sep 17, 2020

Filed:

Feb 25, 2020

Appl. No.:

16/801104

Inventors:

- Mercer Island WA, US
Mary Ann SLAVIK - Mercer Island WA, US
Emily LIN - Mercer Island WA, US

International Classification:

A61N 5/10

Abstract:

A locator for the placement of a fiducial support device for brachytherapy may be used to perform a brachytherapy treatment in which one or more radioactive seeds are implanted into a treatment region of a patient.

US Patent:

20200276451, Sep 3, 2020

Filed:

Feb 25, 2020

Appl. No.:

16/801103

Inventors:

- Mercer Island WA, US
Mary Ann Slavik - Mercer Island WA, US
Emily Lin - Mercer Island WA, US

International Classification:

A61N 5/10

Abstract:

A brachytherapy needle guidance device is a device that facilitates the placement of a brachytherapy needle into a treatment region in tissue. This tissue may a breast tissue and the brachytherapy needle may be a fiducial needle. The brachytherapy needle guidance device may have an anchoring feature that anchors the brachytherapy needle guidance device into the tissue once it is properly positioned. The brachytherapy needle guidance device is used by software for treatment planning.

US Patent:

20200141858, May 7, 2020

Filed:

Oct 15, 2019

Appl. No.:

16/653489

Inventors:

- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US

International Classification:

G01N 15/14
G01N 33/80
G01N 21/64
G01N 33/49

Abstract:

Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

US Patent:

20180322206, Nov 8, 2018

Filed:

Jun 20, 2017

Appl. No.:

15/627963

Inventors:

- Redmond WA, US
Alexandre Bernard Raymond Michelis - Bellevue WA, US
Arun Kumar Sacheti - Sammamish WA, US
Emily Lin - Seattle WA, US
Ryuichi Hirano - Renton WA, US
Vincent Kin-Wah Leung - Bellevue WA, US

Assignee:

Microsoft Technology Licensing, LLC - Redmond WA

International Classification:

G06F 17/30

Abstract:

Methods and systems for providing targeted recommendations are provided. A user model is generated from user data. Feed candidates are generated based on the user model. The generated feed candidates are ranked on a predetermined scale. At least one targeted recommendation from the ranked feed candidates. The at least one targeted recommendation feed is provided to a user associated with the user data.

US Patent:

20180128732, May 10, 2018

Filed:

Sep 14, 2017

Appl. No.:

15/704974

Inventors:

- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US

International Classification:

G01N 15/14
G01N 21/64
G01N 33/49
G01N 33/80
G01N 15/00
G01N 15/10

Abstract:

Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

US Patent:

20160018312, Jan 21, 2016

Filed:

Jul 24, 2015

Appl. No.:

14/808720

Inventors:

- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US

International Classification:

G01N 15/14
G01N 21/64
G01N 33/49

Abstract:

Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.